For example, a recent study demonstrated that [^18F]DCFPyL PET/CT significantly improves the detection of loco-regional disease in patients with advanced PCa who are candidates for radical therapy, ensuring more accurate risk stratification, surgical planning, and more effective prioritization for PSMA-targeted therapies [78]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.